Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Unresectable Gastric Cancer

  • End date
    Dec 30, 2022
  • participants needed
  • sponsor
    Tianjin Medical University Cancer Institute and Hospital
Updated on 26 February 2022


This is a phase II study to evaluate the efficacy and safety of combination of sintilimab (PD-1 inhibitor) , apatinib and chemotherapy in unresectable advanced gastric cancer patients with oligo metastasis. This study was designed as single arm with fixed number of participants.

Condition Gastric Cancer Stage
Treatment apatinib, S1, nab paclitaxel, Sintilimab
Clinical Study IdentifierNCT04267549
SponsorTianjin Medical University Cancer Institute and Hospital
Last Modified on26 February 2022


Yes No Not Sure

Inclusion Criteria

-70 years old
gastroscopy and pathology (histologically/cytologically ) confirmed local advanced or oligo-metastatic gastric adenocarcinoma
m life expectancy
must have at least 1 measurable lesion using RECIST v1.1 criteria
adequate organ function
pregnant test negative of females of childbearing potential , and willing to use adequate contraception
written Informed Consensus Form

Exclusion Criteria

prior use of any checkpoint inhibitor treatment, including with no limited to PD-1, programmed cell death ligand-1(PDL-1), CTLA4 etc
patients with central nervous system, lung, or bone metastasis
Her 2 positive with willing to use herceptin treatment
prior active autoimmune disease or history of autoimmune disease
patients with other malignant tumor
clinically significant cardiovascular and cerebrovascular diseases, including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, or coronary artery bypass surgery, Congestive heart failure (New York heart association (NYHA) class > 2), ventricular arrhythmia which need medical intervention, left ventricular ejection fraction(LVEF) < 50%
not controlled hypertension
prior systemic treatment to metastatic disease
previous digestive tract bleeding history within 3 months or evident gastrointestinal bleeding tendency
patients with or previous with serious hemorrhage
active infection or an unexplained fever
objective evidence of previous or current pulmonary fibrosis history, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, pulmonary function damaged seriously etc
history of immunodeficiency including seropositivity for human immunodeficiency virus (HIV), or other acquired or congenital immune-deficient disease, or active hepatitis
patients who may receive vaccination during study period
mental disorders history, or psychotropic drug abuse history
unable to orally administration
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note